OraSure Technologies, Inc. — Q1 2023 Form 10-Q
Reporting period: Three months ended March 31, 2023; unaudited consolidated results. The company combined its Diagnostics and Molecular Solutions businesses into one operating and reportable segment in February 2023.
Financial performance
| Metric | Q1 2023 | Q1 2022 |
|---|---|---|
| Net revenue | $155.0 million | $67.7 million |
| Gross profit | $65.8 million | $24.3 million |
| Gross margin | 42.5% | 35.9% |
| Operating income (loss) | $24.3 million | ($16.2) million |
| Net income (loss) | $27.2 million | ($19.9) million |
| Diluted EPS | $0.37 | ($0.28) |
| Cash provided by (used in) operations | $6.0 million | ($35.8) million |
Revenue rose 129%, led by COVID-19 Diagnostics revenue of $118.3 million, up 434%, primarily from InteliSwab sales under U.S. government procurement contracts. HIV revenue increased to $13.9 million from $8.2 million. Molecular Products fell 28% to $12.9 million, Molecular Services fell 20% to $1.4 million, and COVID-19 molecular collection-kit revenue fell 98% to $0.2 million.
Gross margin improved mainly due to better InteliSwab manufacturing efficiency, packaging changes, lower freight and lower scrap, partly offset by reduced sales of historically higher-margin COVID-19 molecular products. Other income was $2.7 million versus $0.2 million, largely reflecting DOD contract reimbursements. Q1 2023 included a $1.1 million impairment charge for manufacturing equipment; operating expenses also included $2.6 million in workforce termination costs.
Liquidity, cash flow and liabilities
At March 31, 2023, cash and cash equivalents were $90.2 million and short-term investments were $22.2 million, totaling $112.4 million, versus $110.8 million at year-end 2022. Working capital was $288.5 million, up from $256.1 million. Operating cash flow was positive despite a $36.6 million accounts-receivable increase, largely from government product shipments near quarter-end; inventory declined $18.5 million.
Total liabilities were $65.2 million, including $1.7 million of current and $8.6 million of noncurrent operating lease liabilities, and $1.2 million of current and $0.5 million of noncurrent finance lease liabilities. The filing reports no conventional borrowings in the presented balance sheet. Stockholders’ equity was $394.2 million.
Changes, outlook and risks
- Management expects total product and service revenue to taper off during 2023 as demand for COVID-19 diagnostics declines. The filing provides no specific full-year revenue or earnings guidance.
- The company says existing cash and investments are expected to fund operating expenses and capital needs for at least the next 12 months. It expects to collect the remaining $48.1 million of its $109 million DOD manufacturing-capacity contract funding during 2023; $60.9 million had been received by quarter-end. Final validation testing was scheduled for late 2023.
- Customer concentration is substantial: one non-commercial customer generated 78% of Q1 revenue and represented 77% of accounts receivable at March 31. The filing identifies this customer in the context of government sales but does not name it in the provided text.
- About 65% of cash, cash equivalents and investments was held by Canadian subsidiary DNAG. Management intends to permanently reinvest historical foreign earnings; further repatriation could result in adverse tax consequences.
- In February, the company announced a reduction in its non-production workforce, recording $2.6 million of related expense in Q1. A further May 2023 workforce reduction was estimated to cost $0.5–$0.6 million.
- On May 2, 2023, after quarter-end, a court granted Spectrum Solutions summary judgment of noninfringement in the company’s saliva-device patent litigation. OraSure said it intended to appeal; a patent review and other litigation motions remained pending.
- Risks highlighted include dependence on government and concentrated customers, declining COVID-19 demand, suppliers and manufacturing execution, regulatory approvals, litigation, and potential banking-system disruption. Management reported disclosure controls were effective and no material change in internal control over financial reporting.
Investor facts to verify
- Durability and timing of InteliSwab government orders, customer payments, and the remaining DOD contract funding.
- Revenue and margin trends as COVID-19 test demand declines, including whether HIV and other products can offset that decline.
- Accounts-receivable collectability and the extent of continued reliance on the single major customer.
- Progress and costs for manufacturing-line validation, workforce reductions, and the Spectrum litigation appeal.
- Liquidity availability across jurisdictions, potential tax effects of repatriation, and exposure to financial-institution instability.